MedTrace Logo

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

NCT01882907 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2019-03-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Conditions

Interventions

DRUG

vildagliptin

vildagliptin 50mg bid for 16 weeks

DRUG

Pioglitazone

Pioglitazone 15mg bid for 16 weeks

Sponsors & Collaborators

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • In Ju Kim, MD · Pusan National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01882907 on ClinicalTrials.gov